公开(公告)号：US20220211859A1

公开(公告)日：2022-07-07

申请号：US17608230

申请日：2020-05-07

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ralph Leon BIEMANS ,  Elisabeth Marie Monique BERTAUD

IPC: A61K47/64 ,  A61K39/09 ,  A61P31/04 ,  B01D15/38 ,  B01D15/42

Abstract: This application relates to methods for the production of polysaccharide antigen-carrier protein conjugates, in particular conjugates of Group B Streptococcus (GBS) capsular polysaccharide and a carrier protein, in particular CRM197. The methods comprise a hydroxyapatite chromatography step in order to separate the conjugate from free polysaccharide and free carrier protein.

公开(公告)号：US20240131136A1

公开(公告)日：2024-04-25

申请号：US18386593

申请日：2023-11-01

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Elisabeth Marie Monique BERTAUD ,  Ralph Leon BIEMANS ,  Nicolas Jean Benoit MONIOTTE ,  Laurent Bernard Jean STRODIOT

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6087

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

公开(公告)号：US20240226261A9

公开(公告)日：2024-07-11

申请号：US18386593

申请日：2023-11-02

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Elisabeth Marie Monique BERTAUD ,  Ralph Leon BIEMANS ,  Nicolas Jean Benoit MONIOTTE ,  Laurent Bernard Jean STRODIOT

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6087

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

公开(公告)号：US20180303923A1

公开(公告)日：2018-10-25

申请号：US15769542

申请日：2016-10-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Elisabeth Marie Monique BERTAUD ,  Ralph Leon BIEMANS ,  Nicolas Jean Benoit MONIOTTE ,  Laurent Bernard Jean STRODIOT

IPC: A61K39/09 ,  A61K47/64

CPC classification number: A61K39/092 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6087 ,  A61K2039/62 ,  A61K2039/70

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.